Patents by Inventor Sabine Neirynck
Sabine Neirynck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11633438Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: GrantFiled: February 5, 2020Date of Patent: April 25, 2023Assignee: INTREXON ACTOBIOTICS NVInventors: Sam Corveleyn, Patrick Dhaese, Sabine Neirynck, Lothar Steidler
-
Publication number: 20200171105Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: ApplicationFiled: February 5, 2020Publication date: June 4, 2020Applicant: INTREXON ACTOBIOTICS NVInventors: Sam CORVELEYN, Patrick DHAESE, Sabine NEIRYNCK, Lothar STEIDLER
-
Patent number: 10596207Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: GrantFiled: January 5, 2017Date of Patent: March 24, 2020Assignee: INTREXON ACTOBIOTICS NVInventors: Sam Corveleyn, Patrick Dhaese, Sabine Neirynck, Lothar Steidler
-
Publication number: 20190160119Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: ApplicationFiled: January 5, 2017Publication date: May 30, 2019Inventors: Sam CORVELEYN, Patrick DHAESE, Sabine NEIRYNCK, Lothar STEIDLER
-
Publication number: 20170151292Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: ApplicationFiled: January 5, 2017Publication date: June 1, 2017Inventors: Sam CORVELEYN, Patrick DHAESE, Sabine NEIRYNCK, Lothar STEIDLER
-
Patent number: 9574169Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: GrantFiled: April 28, 2010Date of Patent: February 21, 2017Assignee: INTREXON ACTOBIOTICS NVInventors: Sam Corveleyn, Patrick Dhaese, Sabine Neirynck, Lothar Steidler
-
Patent number: 8759088Abstract: The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.Type: GrantFiled: January 14, 2008Date of Patent: June 24, 2014Assignee: Actogenix N.V.Inventors: Lothar Steidler, Klaas Vandenbroucke, Sabine Neirynck
-
Publication number: 20120039853Abstract: The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications.Type: ApplicationFiled: April 28, 2010Publication date: February 16, 2012Applicant: ACTOGENIX NVInventors: Sam Corveleyn, Patrick Dhaese, Sabine Neirynck, Lothar Steidler
-
Patent number: 7993652Abstract: The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.Type: GrantFiled: June 7, 2010Date of Patent: August 9, 2011Assignee: FVlaams Interuniversitair Instituut Voors BiotechnologieInventors: Sabine Neirynck, Willy Min Jou, Walter Fiers
-
Publication number: 20100297161Abstract: The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.Type: ApplicationFiled: June 7, 2010Publication date: November 25, 2010Inventors: SABINE NEIRYNCK, WILLY MIN JOU, WALTER FIERS
-
Patent number: 7732130Abstract: The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.Type: GrantFiled: March 14, 2006Date of Patent: June 8, 2010Assignee: Vlaams Interuniversitair Instituut Voor BiotechnolgoieInventors: Sabine Neirynck, Willy Min Jou, Walter Fiers
-
Patent number: 7731972Abstract: The present invention relates to an influenza antigen, comprising a fusion product of at least (1) the extracellular part of a conserved influenza membrane protein (e.g., M2) or a functional equivalent thereof and (2) a presenting carrier. The presenting carrier may be a (poly)peptide or a non-peptidic structure such as glycans, peptide mimetics, and synthetic polymers. The invention further relates to methods of making and using the antigen, and to influenza vaccines comprising the antigen and optionally one or more excipients.Type: GrantFiled: February 4, 2000Date of Patent: June 8, 2010Assignee: Vlaams Interuniversitair Instituut Voor BiotechnologieInventors: Sabine Neirynck, Willy Min Jou, Walter Fiers
-
Publication number: 20100080774Abstract: The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the said nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the said nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.Type: ApplicationFiled: January 14, 2008Publication date: April 1, 2010Applicant: ActoGeniX N.V.Inventors: Lothar Steidler, Klaas Vandenbroucke, Sabine Neirynck
-
Publication number: 20080253990Abstract: The invention relates to a recombinant Lactobacillus strain, with limited growth and viability in the environment. More particularly, it relates to a recombinant Lactobacillus that can only survive in a medium where thymidine is present. By this strict dependency upon thymidine, thymidineless death is rapidly induced in this recombinant strain. A preferred embodiment is a Lactobacillus that may only survive in a host organism where thymidine is present, but cannot survive outside the host organism in absence of this medium compound. Moreover, the Lactobacillus strain can be transformed with prophylactic and/or therapeutic molecules and can, as such, be used to treat diseases such as, but not limited to, inflammatory bowel diseases.Type: ApplicationFiled: May 18, 2005Publication date: October 16, 2008Applicant: UNIVERSITY COLLAGE COOKInventors: Lothar Steidler, Sabine Neirynck
-
Publication number: 20060246092Abstract: The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.Type: ApplicationFiled: March 14, 2006Publication date: November 2, 2006Applicant: Vlaams Interuniversitair Instituut Voor BiotechnologieInventors: Sabine Neirynck, Willy Min Jou, Walter Fiers